563 patents currently held
115 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
161 more records may belong here and await a decision; they are not counted.
The next term ends in Feb 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
54
Ending by 2030
Feb 2027
Next term end
316
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2037 · High confidence
Also notable
Ends Aug 2035 · High confidence
Also notable
Ends Feb 2040 · High confidence
GLP-1 Receptor Agonists and Uses Thereof
US 10,208,019
Cited by 56 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2037.
Aminopyrimidinyl Compounds
US 9,663,526
Cited by 53 later US patents, top 10% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
Solid State Forms of (S)-2-(((S)-6,8-Difluoro-1,2,3,4-Tetrahydronaphthalen-2-YL)AMINO)-N-(1-(2-Methyl-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof
US 11,566,006
Cited by 10 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2040.
Formerly held, still cited
Notable
Ends Aug 2028 · High confidence
The most cited patent in this portfolio, cited by 113 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2028.
now held by Codexis, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 21, 2026
- 9 fees due Dec 2 to 30, 2026 · next Dec 2
- 8 fees due Jan 4 to 28, 2027 · next Jan 4
- 10 fees due Feb 1 to 27, 2027 · next Feb 1
- 13 fees due Mar 1 to 29, 2027 · next Mar 1
- 12 fees due Apr 1 to 30, 2027 · next Apr 1
- 8 fees due May 3 to 24, 2027 · next May 3
- 5 fees due Jun 1 to 19, 2027 · next Jun 1
- 13 fees due Jul 2 to 30, 2027 · next Jul 2
- 13 fees due Aug 2 to 27, 2027 · next Aug 2
- 13 fees due Sep 10 to 30, 2027 · next Sep 10
- 10 fees due Oct 7 to 30, 2027 · next Oct 7
- 6 fees due Nov 3 to 12, 2027 · next Nov 3
Recent changes
- Oct 29Assignment recorded on US 12,655,161: Pfizer Inc. to SJP Biotec GmbH Recorded Oct 29, 2026, executed Aug 20, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76561, frame 292.
- Oct 23Assignment recorded on 1 record: Ramirez, Alejandro to Pfizer Inc. Recorded Oct 23, 2026, executed Sep 5, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76486, frame 420.
- 10 of the patents on this record were granted since Aug 16, 2026
- 11 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 316 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Solid State Forms of (S)-2-(((S)-6,8-Difluoro-1,2,3,4-Tetrahydronaphthalen-2-YL)AMINO)-N-(1-(2-Methyl-1-(NEOPENTYLAMINO)PROPAN-2-YL)-1H-IMIDAZOL-4-YL)PENTANAMIDE and Uses Thereof | 11 in force | to Feb 2040 |
| Heteroaromatic Compounds and Their Use as Dopamine D1 Ligands | 9 in force | to Jun 2034 |
| Neisseria Meningitidis Compositions and Methods Thereof | 7 in force | to May 2033 |
| GLP-1 Receptor Agonists and Uses Thereof | 6 in force | to Dec 2037 |
| Glycoconjugation Processes and Compositions | 6 in force | to Jun 2035 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US RE45,847 | Antibodies to Madcam held by Amgen Fremont Inc. In force · Low confidence | In force | Low confidence | |
| US 7,811,263 | Dose Metering Mechanism for an Injection Device In force · High confidence | In force | High confidence | |
| US 9,382,545 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity In force · Medium confidence | In force | Medium confidence | |
| US 7,771,399 | Injection Device with Dose Metering Mechanism with Multiple Anti-Rotation Locking System In force · High confidence | In force | High confidence | |
| US 10,260,071 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity In force · Medium confidence | In force | Medium confidence | |
| US 8,877,761 | Novel N-pyrimidin-4-yl-3-amino-pyrrolo[3,4-c]pyrazole Derivatives as PKC Kinase Inhibitors Grace period ended · Low confidence | Grace period ended | Low confidence | |
| US 9,518,060 | SUBSTITUTED PYRROLO[3,4-c]PYRAZOLES AS PKC KINASE INHIBITORS In force · Medium confidence | In force | Medium confidence | |
| US 10,316,045 | SUBSTITUTED PYRROLO[3,4-c]PYRAZOLES AS PKC KINASE INHIBITORS In force · Medium confidence | In force | Medium confidence | |
| US 11,220,518 | SUBSTITUTED N-PYRIMIDIN-4-YL-3-Amino-PYRROLO[3,4-c]PYRAZOLES AS PROTEIN KINASE C INHIBITORS In force · Medium confidence | In force | Medium confidence | |
| US 11,780,853 | SUBSTITUTED N-PYRIMIDIN-4-YL-3-Aminopyrrolo[3,4-c]PYRAZOLES AS PROTEIN KINASE C INHIBITORS In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 563: 115 patents in force now held by others · 658 patents ended · 291 applications pending · 812 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.